AML FISH PANEL FISH AMLETO inv16 PMLRARA MLL Test
Test Name: AML FISH PANEL FISH AMLETO inv16 PMLRARA MLL Test
Components: Sodium Heparin Vacutainer (2ml)
Price: 2970.0 AED
Sample Condition: Bone marrow / Peripheral blood (Transport immediately)
Report Delivery: 5-7 days
Method: FISH
Test type: Genetics
Doctor: Oncology
Test Department: Pre Test Information
Pre Test Information: AML FISH PANEL (FISH AML/ETO, inv(16), PML/RARA, MLL) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details: The AML FISH panel is a genetic test used to detect specific chromosomal abnormalities associated with acute myeloid leukemia (AML). This panel includes four specific genetic abnormalities:
- AML/ETO: This test detects the presence of a fusion gene between the AML1 (also known as RUNX1) gene and the ETO (also known as RUNX1T1) gene. This fusion gene is found in a subset of AML cases and is associated with a favorable prognosis.
- inv(16): This test detects the presence of an inversion of chromosome 16. This chromosomal abnormality is associated with the fusion gene CBFB-MYH11, which is found in a subtype of AML known as acute myelomonocytic leukemia with abnormal eosinophils (AML-M4Eo).
- PML/RARA: This test detects the presence of a fusion gene between the PML (promyelocytic leukemia) gene and the RARA (retinoic acid receptor alpha) gene. This fusion gene is characteristic of acute promyelocytic leukemia (APL), a subtype of AML that is highly sensitive to treatment with all-trans retinoic acid (ATRA).
- MLL: This test detects rearrangements involving the MLL (mixed lineage leukemia) gene. MLL rearrangements are associated with a poor prognosis in AML, particularly in infants and young children.
The AML FISH panel is used to aid in the diagnosis and risk stratification of AML patients. It provides important information about the specific genetic abnormalities present in the leukemia cells, which can help guide treatment decisions and predict patient outcomes.
Test Name | AML FISH PANEL FISH AMLETO inv16 PMLRARA MLL Test |
---|---|
Components | Sodium Heparin Vacutainer (2ml) |
Price | 2970.0 AED |
Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
Report Delivery | 5-7 days |
Method | FISH |
Test type | Genetics |
Doctor | Oncology |
Test Department: | |
Pre Test Information | AML FISH PANEL (FISH AML/ETO, inv(16), PML/RARA, MLL]) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
Test Details |
The AML FISH panel is a genetic test used to detect specific chromosomal abnormalities associated with acute myeloid leukemia (AML). This panel includes four specific genetic abnormalities: 1. AML/ETO: This test detects the presence of a fusion gene between the AML1 (also known as RUNX1) gene and the ETO (also known as RUNX1T1) gene. This fusion gene is found in a subset of AML cases and is associated with a favorable prognosis. 2. inv(16): This test detects the presence of an inversion of chromosome 16. This chromosomal abnormality is associated with the fusion gene CBFB-MYH11, which is found in a subtype of AML known as acute myelomonocytic leukemia with abnormal eosinophils (AML-M4Eo). 3. PML/RARA: This test detects the presence of a fusion gene between the PML (promyelocytic leukemia) gene and the RARA (retinoic acid receptor alpha) gene. This fusion gene is characteristic of acute promyelocytic leukemia (APL), a subtype of AML that is highly sensitive to treatment with all-trans retinoic acid (ATRA). 4. MLL: This test detects rearrangements involving the MLL (mixed lineage leukemia) gene. MLL rearrangements are associated with a poor prognosis in AML, particularly in infants and young children. The AML FISH panel is used to aid in the diagnosis and risk stratification of AML patients. It provides important information about the specific genetic abnormalities present in the leukemia cells, which can help guide treatment decisions and predict patient outcomes. |